3Irina M, LiLian IP, Cecilia LS, et al. Extrncellar sigoal-kinase and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res, 2001,16: 2050-2056.
4Luckman SP, Hughs DE, Coxon FP, et al. Netrogen-containing bisphosphonates inhabit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res,1998, 13: 1668-1678.
5Fisher JE, Rogers MJ, Hslasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad ,Sci USA, 1999
6Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitroge-containing bisphosphonates. J Pharmacol Exp Ther, 2001, 296: 235-242.
7Frith JC, Monkkonen J, Auriola S, et al. The molecular mechanism of action of the anteresorptive and antiinflammatory drug clodronate: evidence for the formation, in vivo of a metabolite that inhabits bone resorption and causes osteoclast and macrophage a
8Green JR, Clezardifl P. Mechanisms of bisphosphonates effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol, 2002, 25:S3-9.
9Giuliani N, Pedrazzoni M, Passeri G, et al. Bisphosphonates inhibit IL6 production by human ostcoblast-liks cells. Scand J Rheumatol, 1998,27: 38-41.
10Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun, 2002, 291:680-686.
